Clinicians should remain alert for arrhythmias in high-risk patients beginning PCSK9 inhibitor therapy, but such isolated observations should not preclude treatment when cardiovascular benefits outweigh potential risks. This evidence concerns the gene PCSK9 and cardiac arrhythmia.